SFTSV infection marker and application thereof
By using real-time fluorescence quantitative PCR or flow cytometry detection of the internal reference gene of IFITM3 marker and glyceraldehyde-3-phosphate dehydrogenase, the timeliness and coverage of SFTSV infection detection were solved, and early identification of SFTSV infection was achieved and The difference between mild and severe cases is suitable for testing of different strains, reducing the mortality rate and treatment costs of severe cases.
Patent Information
- Application Number
- CN202411094005.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-15
AI Technical Summary
The existing SFTSV infection detection methods have problems such as high timeliness, limited coverage, and inability to identify and distinguish mild and severe diseases early, especially the detection sensitivity and specificity of strains of different genotypes and regions.
Using IFITM3 as a marker, using platelet isolation and real-time fluorescence quantitative PCR or flow cytometry detection, combined with glyceraldehyde-3-phosphate dehydrogenase as an internal reference gene, relative quantitative values were calculated to distinguish SFTSV infection, and through IFITM3 and viral proteins Quantitative data distinguishes between mild and severe.
It overcomes the timeliness and coverage limitations of traditional testing methods, can identify SFTSV infection early and accurately distinguish between mild and severe diseases. It is suitable for testing of all different strains, reducing the mortality rate and treatment costs of severe diseases.
Smart Images

Figure SMS_4 
Figure SMS_7 
Figure HDA0004987344810000011
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology and in vitro detection technology, and in particular to a SFTSV infection marker, and a related detection method, detection kit and application thereof. Background Art
[0002] Severe fever with thrombocytopia syndrome virus (SFTSV) is a new type of tick-borne RNA virus, belonging to the Bunyavirales order, Phenuiviridae family, Bandavirus genus, mainly transmitted by the longhorned tick (Haemophysalis longicornis). SFTSV virus particles are spherical and have an envelope. The genome consists of three independent single-stranded RNA segments, namely S, M and L segments. The disease caused by SFTSV is named severe fever with thrombocytopia syndrome (SFTS). The clinical symptoms are mainly fever, leukopenia, severe thrombocytopenia, abnormal coagulation function, organ failure, especially in severe and / or critical patients, with a mortality rate of 12%-30%. In view of this, SFTS has been included in the "Short List of Infectious Diseases Requiring Priority Research and Intervention" by the World Health Organization. At present, there is a serious lack of understanding of its specific pathogenesis, and there is no approved vaccine or specific medicine for marketing. In addition, the clinical manifestations of SFTS are non-specific. Diseases such as scrub typhus and anaplasmosis can also cause SFTS-like symptoms. Therefore, early identification and detection of SFTS-like symptoms are crucial. For example, after early identification and prediction of severe cases of SFTS, appropriate monitoring and treatment can be given to help reduce the mortality rate of severe and / or critical patients.
[0003] At present, laboratory-specific detection methods for SFTSV include reverse transcriptase (RT) real-time fluorescence quantitative PCR (RT-PCR for short), enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence assay (IFA). RT-PCR confirms whether a patient carries the SFTSV gene by detecting the number of viral RNA copies (viral load) in the patient's serum, but it is only a highly sensitive and specific detection method in the early stage of SFTS because: on the one hand, RT-PCR has high requirements for the timeliness of sample sampling and is limited to within 2 weeks of onset. As the onset time prolongs, the viral nucleic acid in the body will be gradually cleared by the immune system. If the RT-PCR test result is not SFTSV positive after the infection begins, the presence of SFTSV nucleic acid cannot be ruled out. On the other hand, the genetic differences between different genotypes of SFTSV are very large. The RT-PCR technology designed based on the nucleotide sequence of a specific region and a specific SFTSV strain is not sensitive to RT-PCR detection of SFTSV lineages from other regions or strains. Even if an RT-PCR or quantitative RT-PCR with good sensitivity and specificity that can detect two or more strains at the same time is developed, it is still impossible to cover and detect all different strain sequences, and it is impossible to achieve specific detection of all SFTSV strains. Moreover, the RT-PCR detection method has high time cost and large reagent consumption. ELISA and IFA are effective methods for detecting virus-specific IgM and IgG antibodies in serum 7 days after onset of disease. They are used to observe whether IgM antibodies appear, observe the conversion of IgG antibodies in serum, or observe antibody titers. ELISA and IFA also have high requirements for the timeliness of test samples. Generally, IgM and IgG of samples within 2 weeks of onset are required. The sensitivity of IgM and IgG detection is poor. The sensitivity of ELISA is 32-62% and 63-76%, respectively, and the sensitivity of IFA is 53-62% and 58-86%, respectively. Moreover, ELISA and IFA can only detect positive results when the patient's clinical symptoms progress to a more serious level, which is not enough to be used for early identification of SFTSV infection and follow-up detection of disease progression. When the clinical symptoms show typical symptoms of SFTS, there is still a lack of accurate laboratory detection methods for detecting and identifying SFTSV infection and distinguishing between mild and severe SFTS. Therefore, it is urgent to develop a method for early detection and identification of SFTSV infection. For example, a detection method based on SFTSV infection markers.
[0004] In addition to the above-mentioned RT-PCR method and immune method for specific detection of SFTSV viral load, there are many related markers that can be used for laboratory testing after SFTSV infection, including: granulocyte / lymphocyte ratio (NLR), eosinophil percentage (EOS%), basophil percentage (BAS%) and other blood routine, liver and kidney function and other biochemical indexes; platelet count, thrombin time (TT), prothrombin time (PT), fibrinogen (FIB) and other coagulation-related detection markers; or, chymotrypsin (Chymase), 25-hydroxyvitamin D, cystatin C, ferritin, cell-free DNA (cf-DNA) and other unconventional laboratory detection markers; however, no typical markers closely related to SFTSV infection and disease progression have been found. It is well known in the art that interferon-induced transmembrane protein 3 (IFITM3) is a 15kDa membrane-associated protein induced by type I interferon. It is a broad-spectrum cell restriction factor that exists in almost all mammals. IFITM3 can prevent the virus fusion process and plays a very important role in antiviral defense. It has the ability to restrict the invasion of a variety of enveloped viruses including influenza virus, H1N1 virus, West Nile virus, Zika virus, dengue virus, tick-borne encephalitis virus and SARS-CoV-2. It has been reported that platelet IFITM3 is elevated in patients with H1N1 / A influenza infection and is associated with influenza mortality; the expression level of IFITM3 is also associated with the severity of COVID-19, and low expression levels may lead to more severe infections. It can be seen that the expression of IFITM3 is correlated with the condition of viral infection diseases, but there is no clear evidence that the expression of IFITM3 is related to patients diagnosed with suspected SFTSV infection. The present invention aims to find that the expression of IFITM3 in platelets is related to SFTSV infection in the process of screening SFTSV infection markers, and further verify whether IFITM3 can be used as a marker for detecting and identifying SFTSV infection, thereby providing a new identification method for detecting SFTSV infection based on IFITM3 expression and its application in SFTS related detection reagents. Summary of the invention
[0005] The purpose of the present invention is to overcome the defects of existing SFTSV infection detection, provide a new screening method for distinguishing SFTSV infection markers, and develop a detection method for SFTSV infection with better specificity and wider detection coverage based on the screened marker IFITM3.
[0006] In the first aspect, the present invention provides a marker IFITM3 for detecting SFTSV infection. The marker IFITM3 is used to distinguish whether it is SFTSV infection during detection. The detection is implemented in a pretreated blood sample. The pretreatment is to separate platelets from the blood sample to obtain a purified platelet stock solution. The purity of the platelets in the stock solution is greater than 90%.
[0007] According to a preferred embodiment of the present invention, the purity of platelets in the stock solution is 97%.
[0008] According to a preferred embodiment of the present invention, a marker IFITM3 for SFTSV infection detection, wherein the platelets are separated by immunomagnetic bead sorting technology, the steps are as follows: 1) adding a platelet activation inhibitor and mixing, and then centrifuging at a low speed to obtain platelet-rich plasma PRP; 2) pipetting 75% of the platelet-rich plasma PRP for medium-low speed centrifugation, discarding the plasma supernatant, and obtaining a platelet precipitate; 3) preparing a sorting buffer working solution; 4) taking a small amount of the sorting buffer working solution to resuspend the platelet precipitate, adding microbeads in a ratio of sorting buffer working solution: microbeads = 9:1, mixing, and incubating at room temperature; the volume of the incubation solution is counted as a single volume; 5) adding 10 times the volume of the sorting buffer working solution, mixing again, centrifuging at a medium-low speed, discarding the supernatant, and obtaining a microbead-labeled platelet precipitate; 6) taking 2-3 times the volume of the sorting buffer working solution volume of sorting buffer working solution to resuspend the platelet sediment to obtain a platelet suspension; 7) take the microcolumn and place it on a magnetic separator, add 2-3 times the volume of sorting buffer working solution to rinse the microcolumn once, and discard the waste liquid; 8) add the platelet suspension to the microcolumn for magnetic adsorption, repeat the magnetic adsorption operation twice, and discard the platelet suspension flowing out of the microcolumn after the second magnetic adsorption; 9) take 2-3 times the volume of sorting buffer working solution to rinse the microcolumn, and repeat the rinsing operation 3 times; 10) remove the microcolumn from the magnetic separator, place it on a new centrifuge tube, add 5 times the volume of sorting buffer working solution to make the platelets adsorbed in the microcolumn flow out with the sorting buffer working solution to the centrifuge tube below, and obtain a single cell suspension, which is the purified platelet; 11) use flow cytometry to detect the purity of the platelets on the single cell suspension.
[0009] According to a preferred embodiment of the present invention, the centrifuge is preferably a horizontal centrifuge, and the centrifugation settings are: the centrifugation temperature is room temperature; the centrifugal force of low-speed centrifugation is 200g, and the centrifugal force of medium-low speed centrifugation is 800×g; the centrifugation time defaults to 5 minutes, and the slowest speed is level 3.
[0010] In a second aspect, the present invention provides a real-time fluorescence quantitative PCR detection method for differentiating SFTSV infection, using the marker IFITM3 as the amplification target gene and glyceraldehyde-3-phosphate dehydrogenase GAPDH as the amplification internal reference gene, calculating the relative quantitative value through the amplification result of IFITM3 relative to glyceraldehyde-3-phosphate dehydrogenase GAPDH, and being used to differentiate whether it is SFTSV infection.
[0011] In a third aspect, the present invention provides a real-time fluorescence quantitative PCR detection kit for differentiating SFTSV infection, using the marker IFITM3 as the amplification target gene. Among them, the primers of the marker IFITM3 are H-IFITM3-F and H-IFITM3-R, and the corresponding nucleotide sequences are shown as SEQ ID NO:1 and SEQ ID NO:2 in the sequence listing; using glyceraldehyde-3-phosphate dehydrogenase GAPDH as the amplification internal reference gene, and the primers of the glyceraldehyde-3-phosphate dehydrogenase GAPDH are GAPDH-F and GAPDH-R, and the corresponding nucleotide sequences are shown as SEQ ID NO:3 and SEQ ID NO:4 in the sequence listing.
[0012] In a fourth aspect, the present invention provides a flow cytometry detection method for differentiating SFTSV infection, using the SFTSVNP protein and the marker IFITM3 together as the target proteins for detection, and using the quantitative values of SFTSVNP and the marker IFITM3 as the differentiation criteria for differentiating SFTSV infection.
[0013] According to a preferred embodiment of the present invention, the quantitative value is the sum value of the positive percentage expressions of IFITM3 and SFTSVNP obtained by flow cytometry detection, denoted as M; the sum value corresponding to the negative detection sample is M1, and the sum value corresponding to the positive detection sample is M2.
[0014] Preferably, the differentiation criteria include: if the quantitative value M2≥M1±SD, the detection result is determined to be positive; and among the positive cases, if the quantitative value M1±SD<M2≤0.12±0.08%, the detection result is determined to be mild SFTS; if the quantitative value M2>0.12 + 0.08%, the detection result is determined to be severe SFTS.
[0015] More preferably, M1±SD = 0.02±0.01%.
[0016] In the fifth aspect, the present invention provides a flow cytometric detection kit for distinguishing SFTSV infection, wherein the detection sample is purified platelets; SFTSVNP protein and marker IFITM3 are used as target proteins for detection; the flow cytometric detection kit includes IFITM3 monoclonal antibody, SFTSVNP polyclonal antibody, two differently labeled secondary antibodies corresponding to the IFITM3 monoclonal antibody and SFTSVNP polyclonal antibody, and flow cytometric detection supporting reagents.
[0017] According to a preferred embodiment of the present invention, the secondary antibody is a goat anti-mouse secondary antibody corresponding to the IFITM3 monoclonal antibody, and a goat anti-rabbit secondary antibody corresponding to the SFTSVNP polyclonal antibody; the two different markers are either FITC marker and APC marker, or AlexaFluor 488 marker and Alexa Fluor 647 marker; the flow cytometry detection supporting reagents include flow cytometry fixed membrane permeabilization fluid and flow cytometry membrane permeabilization buffer.
[0018] In a sixth aspect, the present invention provides a use of a marker IFITM3 in preparing a kit for detecting SFTSV infection, wherein the kit adopts either an RT-PCR method or an immunological method.
[0019] Beneficial effects of the present invention:
[0020] The present invention provides an SFTSV infection marker IFITM3 that is upregulated in platelet samples from subjects diagnosed with SFTS. Based on the SFTSV infection marker IFITM3, an internal reference gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) is introduced to provide a real-time fluorescence quantitative PCR detection method for distinguishing SFTSV infection and a real-time fluorescence quantitative PCR detection kit for distinguishing SFTSV infection. The real-time fluorescence quantitative PCR detection can be used to assist in distinguishing whether subjects from whom platelet samples are derived and whose clinical symptoms are fever with thrombocytopenia are infected with SFTSV, thereby overcoming the strict requirements of traditional SFTSV nucleic acid detection on sample timeliness and the limitation on sequence coverage of unknown strains. Furthermore, by comparing the expression level of the SFTSV infection marker IFITM3 in the platelet samples, the expression level of IFITM3 in the samples collected from SFTS severe subjects was higher than that in the samples from SFTS mild subjects. By jointly detecting the SFTSVNP protein and the marker IFITM3, the present invention also provides a flow cytometric detection method and a corresponding flow cytometric detection kit for distinguishing whether SFTSV infection has progressed to severe SFTS. The present invention also clarifies the quantitative distinction standard of the flow cytometric detection results, and clarifies the quantitative values of SFTSVNP and the marker IFITM3 as the distinction standard for distinguishing SFTSV infection. Therefore, based on the joint detection of SFTSVNP and the marker IFITM3, it can not only be used to distinguish SFTSV infection, but also can be used to further distinguish whether the subject from which the sample is derived is a mild SFTS or a severe SFTS, especially for early distinction and identification of those who may progress to severe SFTS, which will have good clinical application value.
[0021] The present invention provides a new idea for using IFITM3 on platelets as a marker to assist in the detection and differentiation of SFTS from scrub typhus, anaplasmosis, etc. The present invention found through transcriptome sequencing and Western blot experiments that compared with negative samples, IFITM3 expression was significantly increased in the platelets of SFTS patients, which has the potential to assist in the early detection of SFTS. The feasibility of IFITM3 for early detection and identification of SFTS has been verified through clinical samples, and it can be better used for early auxiliary detection and identification of clinical symptoms such as fever with thrombocytopenia, and provide a more accurate basis for the selection of subsequent antiviral drugs or treatment strategies.
[0022] Based on the detection of the SFTSV infection marker IFITM3, whether it is real-time fluorescence quantitative PCR detection or flow cytometry detection, the purpose of distinguishing SFTSV infection can be achieved by collecting the marker IFITM3 on the platelets after pretreatment of the blood samples from the subjects. It not only overcomes the shortcomings of the existing technology, but also has low requirements on the timeliness of sample sampling, and is no longer limited to within 2 weeks of onset. It can cover the entire process of detecting SFTSV infection. Even if the onset time is prolonged, as long as SFTSV infection still exists, the platelet marker IFITM3 will be upregulated, and it can be distinguished whether it is SFTSV infection through relevant detection of the marker IFITM3; and because the detection target is the stress response of the subject's platelets to SFTSV, it can cover the detection of all different SFTSV virus strains, overcoming the limitations of traditional nucleic acid detection on genetic differences between SFTSV of different genotypes.
[0023] The present invention provides the application of SFTSV infection marker IFITM3 combined with viral protein (SFTSVNP) in distinguishing SFTSV infection, and further distinguishes SFTS mild and severe cases by quantitative data of marker protein expression on platelets and double positive with viral protein, filling the gap of laboratory detection methods for distinguishing the disease progression of SFTS diagnosed patients. The test results of the present invention can be used to assist in distinguishing the severity of the patient's disease progression, or to optimize more products based on the development of marker IFITM3, such as the development of IFITM3 corresponding to the marker IFITM3. Related technologies such as antibody probes for detection, further improve early related diagnostic reagents and prediction systems, for medical staff to refer to the test results and combine the specific disease progression of the subject, and then targeted early diagnosis and early treatment.
[0024] Considering the typical symptoms of thrombocytopenia, there is no technical inspiration for testing the platelets of subjects. The present invention overcomes the limitation of the traditional detection target of pathogen SFTSV in samples collected from subjects, and creatively selects closely related subsequent markers from platelets for detection. The method of the present invention is based on the quantitative relationship between the positive expression of IFITM3 protein and viral protein in platelets to distinguish the condition of patients with severe fever with thrombocytopenia syndrome (SFTS). From the perspective of the stress response of the subjects, it is conducive to being widely used in multiple fields such as diagnostic reagent development, drug development, and gene expression regulation research, and provides auxiliary technical support for a more in-depth study of the virus prevention, control, and diagnosis and treatment of SFTSV, and lays a positive application foundation.
[0025] Through the detection method after platelet separation provided in this application, due to the up-regulated expression of SFTSV infection marker IFITM3 at the transcriptional level and protein level, the feasibility of IFITM3 on platelets as a candidate marker for detection was verified by real-time fluorescence quantitative PCR and flow cytometry detection methods, respectively. The experimental results of the two detection methods not only confirmed the up-regulated expression of marker IFITM3 in platelets of subjects infected with SFTSV, but also compared with negative samples, the positive rate of marker IFITM3 up-regulated expression was significantly increased. Furthermore, a method for distinguishing the disease progression of SFTS confirmed patients by flow cytometry based on SFTSV infection markers is provided, which can distinguish SFTS severe cases as soon as possible, and combine viral proteins and platelet counts, etc., which is conducive to determining accurate, practical, and targeted treatment plans as soon as possible, reducing the occurrence of complications, reducing total treatment costs, improving cure rates, and reducing severe mortality. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 The volcano plot of gene differential expression (p<0.05) under two different conditions and the scatter plot of IFITM3 gene expression abundance are shown in the present invention based on the high-throughput sequencing results; Figure 1 In A, the horizontal axis: log2FoldChange is the logarithmic value of the gene expression difference fold, and the vertical axis: p-value is the negative logarithmic value of p-value; Figure 1 In B, the horizontal axis represents that the samples come from two different conditions: "H" = Healthy, which is a healthy donor, and "P" = Patients, which is a severe SFTS patient; the vertical axis is the IFITM3 gene expression abundance (TPM); "**" indicates a significant difference;
[0027] Figure 2 This is a graph showing the expression results of IFITM3 under two different conditions detected by flow cytometry in the present invention, wherein the horizontal axis represents that the samples come from two different conditions: "H" = Healthy, which is a healthy donor, and "P" = Patients, which is a patient diagnosed with SFTS; the vertical axis is the percentage of IFITM3 expression; "****" means that the difference is extremely significant;
[0028] Figure 3 The graphs are the results of IFITM3 protein expression in negative samples and positive samples of different process states verified by Western blot experiments of the present invention. The upper part is the Western blot experiment result graph, and the lower part is the immunoblot grayscale bar analysis graph drawn according to the Western blot experiment results, wherein the horizontal axis represents samples from three different categories: "H" = Healthy, for healthy donors, "M" = Mild, for SFTS mild disease, and "S" = Severe, for SFTS severe disease;
[0029] Figure 4 The figure is a test result diagram of 44 clinical samples by the real-time fluorescence quantitative PCR detection method for SFTSV infection of the present invention, the horizontal axis represents the clinical diagnosis background from which the samples come: "H" = Healthy, for healthy donors, "P" = Patients, for patients diagnosed with SFTS; the vertical axis is the relative quantitative logarithmic value of the amplification of the marker IFITM3 relative to the internal reference gene GAPDH; "****" means the difference is extremely significant;
[0030] Figure 5 This is a graph showing the test results of 8 negative samples detected by flow cytometry in the present invention;
[0031] Figure 6 This is a graph showing the test results of flow cytometry testing of samples from 14 patients diagnosed with mild SFTS in the present invention;
[0032] Figure 7 This is a graph showing the test results of flow cytometry testing of samples from 22 patients diagnosed with severe SFTS in the present invention;
[0033] Figure 5-Figure 7 In the middle, the abscissa is FITC-IFITM3, and the ordinate is APC-SFTSVNP;
[0034] Figure 8 It is an analysis diagram of the flow cytometry test result data of 44 clinical samples in the present invention; A is a relationship diagram of the co-expression of IFITM3 protein and viral NP protein in samples of different process states in the flow cytometry test results, and the horizontal axis represents samples of different process states from SFTS confirmed patients: "M" = Mild, mild SFTS, "S" = Severe, severe SFTS; the vertical axis is the logarithm of the sum of the flow cytometry value percentages of the marker IFITM3 and the viral NP protein; "*" indicates significant difference; B is the correlation between the expression levels of IFITM3 protein and viral NP protein in the flow cytometry test results, the horizontal axis is the flow cytometry value percentage of the marker IFITM3 expressed alone, and the vertical axis is the flow cytometry value percentage of the viral NP protein expressed alone. DETAILED DESCRIPTION
[0035] Exemplary embodiments of the present invention are described in detail below in conjunction with the accompanying drawings, wherein the same or similar terms represent the same concepts, such as severe fever with thrombocytopenia syndrome = SFTS, severe fever with thrombocytopenia syndrome virus = SFTSV, interferon-induced transmembrane protein 3 = IFITM3, and single cell suspension = purified platelets.
[0036] In the following detailed description, for ease of explanation, numerous specific details are set forth to provide a comprehensive understanding of the embodiments of the present disclosure. The following embodiments are only used to illustrate the present invention and should not be considered to limit the scope of the present invention.
[0037] The experimental methods used in the following examples are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all available from commercial sources unless otherwise specified. Among them, the severe febrile thrombocytopenia syndrome virus nucleic acid detection kit adopts the qRT-PCR probe method and is purchased from DAAN GENE; the model of the horizontal centrifuge is Sorvall ST1 Plus, 120-240VTX-400 (Cat. No.: 75016030), the speed is adjustable, the fastest is 9 gears, the slowest is 1 gear, purchased from ThermoScientific; prostaglandin E1 (PGE1 for short) is purchased from Cayman; the blood collection tube is selected with a black cap, which is a sodium citrate erythrocyte sedimentation rate test tube for platelet separation or erythrocyte sedimentation rate test, in which the ratio of sodium citrate anticoagulant to blood is 1:49, purchased from Wuhan Zhiyuan Medical Co., Ltd.; the magnetic bead kit contains microbeads (immune microbeads coupled to antibodies, specifically human CD61 microbeads), microcolumns, BSA stock solution, and cleaning solution. Solution), and magnetic separator, purchased from Miltenyi Biotec; RNA extraction kit RNAiso Plus, purchased from TaKaRa; reverse transcription kit IIIAll-in-one RT SuperMix Perfect for qPCR (Cat. No. R333) and qPCR premix were high-yield, platform-universal TaqPro Universal SYBR qPCR Master Mix (Cat. No. Q712), both purchased from Nanjing Vazyme Biotechnology Co., Ltd. (Vazyme); the real-time fluorescence quantitative PCR instrument was StepOnePlus TMReal-Time PCR System was purchased from Applied Biosystems, USA; Qubit RNA HS detection kit and Qbit 4.0 fluorometer were purchased from Invitrogen; Stranded mRNA Library Prep was purchased from Illumina; high-throughput sequencing was commissioned to the Institute of Hydrobiology, Chinese Academy of Sciences using the HiSeq 3000 platform; peroxide substrate (Thermo SuperSignal West Pico substrate) was purchased from Thermo Scientific; the color development system (Bio-imaging System) was the MicroChemi system for high-end gel imaging, purchased from DNR, Israel; the flow cytometer model was BD FACSCanto TM II, purchased from BD Biosciences; flow fixation / permeabilization solution (Fixation / Permeabilization) and flow permeabilization buffer (Permeabilization Buffer) were purchased from eBioscience; IFITM3 monoclonal antibody (model 66081-Ig) was purchased from Proteintech; SFTSVNP polyclonal antibody was a rabbit polyclonal antibody prepared and stored in the laboratory of the applicant; goat anti-rabbit secondary antibody (Alexa 647-labeled goat anti-rabbit IgG H&L) and goat anti-mouse secondary antibody (Alexa 488 labeled goat anti-mouse IgG H&L) was purchased from Abcam. However, it is obvious that one or more embodiments can be implemented without these specific details, and if no specific conditions are specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer.
[0038] The molecular biology experimental methods not specifically described in the following embodiments are all carried out with reference to the specific methods listed in the book "Molecular Cloning Experiment Guide" (3rd edition) by J. Sambrook, or in accordance with the kit and product instructions. The detection object in the implementation of the present invention is an inanimate biological sample collected from a human or animal body and separated from the human or animal body, such as a platelet sample obtained by separation after collecting a whole blood sample. The whole blood samples involved in the present invention include negative samples and positive samples; wherein, the negative samples are derived from whole blood samples of healthy donors, and the positive samples are derived from whole blood samples diagnosed with clinical SFTS; all whole blood samples are derived from subjects whose sample retention date is between 2023 and 2024. The SFTS diagnosis process includes but is not limited to: first, comprehensively judge the clinical symptoms and routine laboratory test parameters (such as platelets, etc.) as suspected cases of severe fever with thrombocytopenia syndrome; then use the severe febrile thrombocytopenia syndrome virus nucleic acid detection kit to test the serum samples of suspected cases, and the positive results can be determined as confirmed cases of SFTS infected with SFTSV. The direct purpose of the test is to verify the expression of IFITM3 (interferon induced transmembrane protein 3), a marker of SFTSV infection, in the sample to be tested, and to provide auxiliary data for clinical diagnosis. The steps of the entire test method do not include the steps of obtaining the diagnosis results of the disease or the conclusion / step of the health status. Therefore, the test involved in the present invention does not belong to the diagnostic method of the disease, and meets the basic requirements of the Patent Law for the subject matter of patent protection.
[0039] The present invention discloses a screening and verification process of IFITM3, a candidate marker for SFTSV infection, and uses IFITM3 on platelets as a marker for detecting SFTSV infection, providing two typical detection methods and detection kits for distinguishing SFTSV infection, which are used to assist in distinguishing SFTS infection from scrub typhus, anaplasmosis, etc. Based on the application of the marker IFITM3, a real-time fluorescence quantitative PCR detection method and a corresponding real-time fluorescence quantitative PCR detection kit are provided by introducing the internal reference gene GAPDH; a flow cytometry detection method and a corresponding flow cytometry detection kit are provided by jointly detecting the SFTSVNP protein and the marker IFITM3, which can be used not only to distinguish SFTSV infection, but also to distinguish whether SFTSV infection has the possibility of progressing to severe SFTS. The specific embodiments of the present invention are described in detail below, and the specific contents are as follows:
[0040] Example 1. Separation of platelets
[0041] Take a whole blood sample collected from a black cap blood collection tube, use immunomagnetic bead sorting technology (MACS) to separate platelets, and obtain purified platelets. The specific steps of platelet separation are as follows:
[0042] 1) Add a platelet activation inhibitor to a blood collection tube at a ratio of 1:1000, mix well, and centrifuge at a low speed to obtain platelet-rich plasma (PRP); the platelet activation inhibitor is preferably PGE1, for example, 3 μL PGE1 can be added to a blood collection tube containing 3 mL of whole blood sample, gently shake to mix well, and then place in a centrifuge for low-speed centrifugation; the supernatant obtained after centrifugation is PRP;
[0043] 2) Pipette 75% of the PRP into a new centrifuge tube, place it in a centrifuge for medium-low speed centrifugation, discard the plasma supernatant, and the precipitate at the bottom of the centrifuge tube is the unpurified platelet precipitate;
[0044] 3) Prepare the sorting buffer working solution: dilute the BSA stock solution with the cleaning solution at a dilution ratio of 1:20, and then add the platelet activation inhibitor at a ratio of 1:1000; wherein the platelet activation inhibitor is preferably PGE1;
[0045] 4) Take 180 μL of sorting buffer to resuspend the platelet pellet, then add 20 μL of beads and mix well (180 μL + 20 μL = 200 μL), and incubate at room temperature for 15 min;
[0046] 5) Add 2 mL of sorting buffer solution, mix well, centrifuge at medium to low speed, discard the supernatant, and obtain the microbead-labeled platelet precipitate;
[0047] 6) Take 500 μL of sorting buffer working solution to resuspend the platelet precipitate to obtain a platelet suspension;
[0048] 7) Place the microcolumn on the magnetic separator, add 500 μL of separation buffer solution to rinse the microcolumn once, and discard the waste solution;
[0049] 8) The platelet suspension is subjected to a second magnetic adsorption in the microcolumn: the platelet suspension is added to the microcolumn, and the platelets labeled with microbeads are subjected to a first magnetic adsorption under the magnetic force of the magnetic separator; the platelet suspension flowing out after the first magnetic adsorption is recovered below the microcolumn, and is added to the microcolumn again for a second magnetic adsorption to increase the yield of magnetic adsorption of platelets, and the platelet suspension flowing out of the microcolumn after the second magnetic adsorption is discarded;
[0050] 9) Rinse the microcolumn 3 times: Take 500 μL of sorting buffer solution to rinse the microcolumn each time, discard the waste solution, and repeat the rinsing 3 times;
[0051] 10) Remove the microcolumn from the magnetic separator and place it in a new centrifuge tube. Add 1 mL of sorting buffer to allow the platelets adsorbed in the microcolumn to flow out into the centrifuge tube below along with the sorting buffer. The obtained single cell suspension is the purified platelet.
[0052] In the platelet separation step, the new centrifuge tube is preferably a clean 15 mL centrifuge tube; the sorting buffer working solution that flows out after flushing the microcolumn is waste liquid, and a centrifuge tube for collecting waste liquid can be placed under the microcolumn;
[0053] 11) Flow cytometry was used to detect the purity of platelets in single cell suspension.
[0054] The specific steps of platelet purity detection are as follows: take a single cell suspension in a 96-well plate, 100 μL / well, then add the coupled antibody at 1 μL / well, incubate at room temperature for 15 minutes, centrifuge at medium-low speed, and discard the supernatant after centrifugation; add 200 μL / well PIPES buffer to wash the precipitate, centrifuge at medium-low speed again, and discard the supernatant again after centrifugation; then add 100 μL / well PIPES buffer to resuspend the precipitate, and perform platelet purity detection in a flow cytometer. Among them, the coupled antibody is directly coupled to CD41 monoclonal antibody; the operation of washing the precipitate should be gentle and avoid violent shaking to prevent damage to the platelets. After the washing step, the morphology and activity of the cells can be checked to ensure that the washing operation has no significant effect on the platelets; the resuspended precipitate should ensure that the suspension is mixed evenly, without bubbles and clots, so as not to affect the reading of the flow cytometer; if conditions permit, the suspension can be filtered before entering the flow cytometer analysis to remove impurities that may interfere with the detection; the voltage of the flow cytometer is set to: forward scattered light (FSC) 150V, side scattered light (SSC) 350V, FITC 550V, APC 600V. The laser wavelength of FITC is 488nm, the laser wavelength of APC is 633nm, and the gain and threshold are set to 0 and 5000 respectively to ensure the maximum accuracy in distinguishing target cells (platelets) and non-target cells.
[0055] In a specific embodiment of the present invention, the default centrifugation conditions for "low-speed centrifugation" and "medium-low-speed centrifugation" are: the centrifuge is preferably a horizontal centrifuge, and the centrifugation settings are: the centrifugation temperature is room temperature; the centrifugal force of low-speed centrifugation is 200g, and the centrifugal force of medium-low-speed centrifugation is 800×g; the centrifugation time defaults to 5min, and the speed increase and decrease is set to 3 gears.
[0056] In order to further improve the accuracy of subsequent tests, the purity of platelets after separation is required to be higher, with the purity of platelets being at least greater than 90%, and the purity of platelets being greater than 97% being optimal.
[0057] Example 2, SFTSV infection marker IFITM3
[0058] (1) High-throughput sequencing and discovery of the SFTSV infection marker IFITM3
[0059] The blood samples came from 4 positive samples (clinically confirmed SFTS patients) and 4 negative samples (healthy donors). After obtaining purified platelets from these 8 blood samples according to the above platelet separation steps, platelet RNA was extracted and a platelet RNA library was built. Finally, transcriptome high-throughput sequencing was used to analyze and verify the correlation between SFTSV infection and the marker IFITM3.
[0060] First, RNA was extracted from the separated platelets using an RNA extraction kit, and the extraction steps were as follows: 400 μL of RNAiso Plus was added to the platelets, and the mixture was mixed thoroughly and allowed to stand for 5 minutes to allow the collected platelets to completely lyse; 200 μL of chloroform was added to the mixture for RNA extraction, and the mixture was vigorously mixed on an oscillator and centrifuged at 4°C and 13000g for 15 minutes; 200 μL of supernatant was taken into a new 1.5 mL EP tube, and an equal volume of pre-cooled isopropanol was added and mixed thoroughly, and the mixture was placed at -80°C to precipitate RNA; after standing for 30 minutes, the mixture was centrifuged again at 4°C and 13000g for 15 minutes; the supernatant was discarded, and the precipitate was washed with 1 mL of 75% alcohol prepared with DEPC, and then centrifuged at 4°C and 13000g for 5 minutes, and the washing and centrifugation were repeated once; the supernatant was discarded, and the precipitate was allowed to stand at 65°C for about 5 minutes until the precipitate changed from white to colorless and transparent; 20 μL of DEPC water was added to dissolve the precipitate to obtain platelet RNA.
[0061] Secondly, the platelet RNA was quantitatively tested using the Qbit4.0 fluorometer and QubitRNAHS detection kit. The detection steps refer to the product manual. The extracted platelet RNA sample was tested and the RNA concentration was greater than 50ng / μL. 50-100ng of RNA sample was taken and the second-generation sequencing library was constructed using the Illumina StrandedmRNAPrep kit. The library construction steps refer to the product manual; finally, the sequencing library was subjected to high-throughput sequencing. The sequencing work was commissioned by the Institute of Hydrobiology, Chinese Academy of Sciences using the HiSeq3000 analysis and testing platform, requiring the sequencing throughput of each sample to be no less than 5G.
[0062] According to the high-throughput sequencing results obtained, the raw data corresponding to the positive and negative samples were compared. From data quality control to gene expression quantification, to differential gene screening and functional annotation, the high-throughput sequencing data were analyzed in a complete and rigorous manner, which is specifically reflected in the following aspects: ① Strict data quality control: In order to ensure data reliability, FastQCv0.12.1 was used to evaluate the quality of raw data. In order to reduce the impact of sequencing errors and noise on subsequent analysis, Trimomaticv0.36 was used to filter low-quality reads until the data quality control was qualified. ② Accurate gene expression quantification: HISAT2 v2.0.4 was used to align the sequence to the reference genome GRCh38.p14, and HTSeq v0.12.4 was used to quantify the gene expression level, laying the foundation for subsequent differential analysis. ③ Rigorous statistical analysis: DESeq2 v1.42.0 was used to homogenize the samples and eliminate batch effects to ensure the accuracy of subsequent differential analysis; scientific and strict screening criteria for differential genes were set (FoldChange greater than 1 or less than -1, and the threshold of q-value (false discovery rate) was set to 0.05), which is conducive to identifying statistically significant changes in gene expression. Under two different conditions (SFTS critically ill patients and healthy donors), FoldChange is an indicator of the degree of quantitative change in gene expression. FoldChange greater than 1 indicates an upregulated gene, and less than -1 indicates a downregulated gene. ④ In-depth analysis of the functions of differentially expressed genes: Functional annotation of differentially expressed genes through Metascape and Gene Ontology (GO) helps to fully understand the role of differentially expressed genes in biological processes, as well as the mechanisms or physiological processes in which these differentially expressed genes participate in specific diseases. The results of transcriptome data analysis are as follows: Figure 1 A volcano plot of differential gene screening is shown as follows: below the horizontal dotted line are genes with no difference in expression between the negative and positive samples; on the right (above the horizontal dotted line, to the right of the 2nd vertical dotted line), it can be seen that compared with the negative samples, there are 149 up-regulated genes that are significantly enriched in the positive samples; on the left (above the horizontal dotted line, to the left of the 1st vertical dotted line), it can be seen that compared with the negative samples, there are 60 down-regulated genes that are significantly inhibited in the positive samples; among the up-regulated genes, the transcription level of IFITM3 has the highest degree of change, that is, IFITM3 can be used as a typical representative of differential genes; according to Figure 1 The scatter plot of IFITM3 gene expression abundance under two different conditions shown in B shows that the IFITM3 gene expression abundance (TPM) from severe SFTS patients is more than 89.79 times higher than that from healthy donors, further proving that IFITM3 is upregulated in severe SFTS patients, that is, IFITM3, as one of the most significantly upregulated genes, can be used as a candidate marker for SFTSV infection and further verified at the protein level and in clinical samples.
[0063] (2) Flow cytometry and verification of IFITM3 expression differences
[0064] Blood samples were also derived from 4 positive samples (clinically confirmed SFTS patients) and 4 negative samples (healthy donors). After obtaining purified platelets according to the above platelet separation steps, flow cytometry was used to verify the correlation between the expression of the candidate marker IFITM3 in the platelets of SFTS patients. The specific operation of the flow cytometry experiment is as follows:
[0065] 1) Take out 100 μL / well of the separated single cell suspension (purified platelets) and place it in a 96-well plate;
[0066] 2) Add 200 μL / well flow cytometry permeabilization buffer to resuspend evenly, incubate at room temperature in the dark for 30 minutes, centrifuge at medium to low speed, and discard the supernatant;
[0067] 3) Add 200 μL / well 1× flow cytometry permeabilization buffer and centrifuge at room temperature at medium to low speed, and discard the supernatant;
[0068] 4) Add 1× flow cytometry permeabilization buffer to adjust the volume to 100 μL / well and resuspend;
[0069] 5) Add IFITM3 monoclonal antibody at a ratio of 1:2000, incubate at room temperature in the dark for 30 minutes, centrifuge at medium to low speed, and discard the supernatant;
[0070] 6) Add 1× flow cytometry permeabilization buffer again to adjust the volume to 100 μL / well and resuspend;
[0071] 7) Add goat anti-mouse secondary antibody at 1:2000, incubate at room temperature in the dark for 15 minutes, centrifuge at medium to low speed, and discard the supernatant;
[0072] 8) After adding 100 μL PIPES buffer to resuspend the cells, load the cells onto a flow cytometer for detection and analysis;
[0073] The purified platelets were separated and analyzed by flow cytometry. Figure 2 As shown: It was further confirmed that IFITM3 was upregulated in platelets of severe SFTS patients, and the IFITM3 positivity rate was significantly increased compared with healthy donors (p<0.01), that is, IFITM3 was significantly upregulated.
[0074] (3) Western blot experiment and verification of the expression difference of IFITM3, a marker of different processes
[0075] The blood samples included negative samples (healthy donors) and positive samples with different process states (clinically determined mild SFTS and severe SFTS). The 9 randomly selected blood samples included 3 negative samples, 3 mild SFTS and 3 severe SFTS. After the purified platelets were obtained from these 9 blood samples according to the above-mentioned platelet separation steps, the Western blot experiment was used to analyze and verify the expression differences of the marker IFITM3 in the positive samples with different process states.
[0076] First, take the purified platelets, add protein loading and place at 95°C for 10 minutes to fully lyse them; centrifuge at 4°C and 13,000×g for 1 minute, and freeze the processed supernatant samples at -80°C or directly perform Western blot experiments.
[0077] The experimental steps of Western blot were as follows: the supernatant sample was loaded for 12% SDS-PAGE electrophoresis, and after the electrophoresis, the membrane was transferred to a polyvinylidene difluoride membrane (PVDF, Millipore), and then blocked with 5% skim milk at 37°C for 1 hour, and then the blocking solution was discarded. The membrane was washed with TBST buffer (50mM Tris-Cl, 200mM NaCl, 0.5% Tween20, pH 7.5) at room temperature for 5 minutes, and the TBST buffer was discarded; the primary antibody (anti-IFITM3) was diluted to an appropriate concentration with Western primary antibody diluent (Beyotime Biotechnology, P0023A), and the PVDF membrane was immersed in the primary antibody diluent and incubated at 37°C for 2 hours or at 4°C overnight; after washing the membrane with TBST buffer for 5 times, HRP-labeled secondary antibody was added and incubated at room temperature for 1 hour; after washing the membrane with TBST buffer, the results were observed using a peroxide substrate (Chemiluminescent Substrate) and a color development system (Bio-imaging System). The blot experiment results are as follows Figure 3 As shown, the primary antibody also includes control antibodies: anti-βactin and anti-SFTSVNP. In order to highlight the main purpose of the Western blot experiment of the present invention, the experimental results of the control antibodies are not shown. According to the results of the Western blot experiment, it can be seen that compared with the negative samples, the expression of IFITM3 protein in patients diagnosed with SFTS is significantly upregulated; and according to the bar analysis chart of the grayscale of the immunoblot drawn according to the results of the Western blot experiment, it can be seen that the expression of IFITM3 protein is significantly different in different disease processes of patients diagnosed with SFTS, that is, the upregulation level of IFITM3 protein expression in severe SFTS is significantly higher than that in mild SFTS.
[0078] Example 3: Application of SFTSV infection marker IFITM3
[0079] The present invention established RT-PCR and flow cytometry detection platforms for the SFTSV infection marker IFITM3, and tested and verified 44 randomly selected blood samples. All 44 blood samples had clear clinical backgrounds: 8 negative samples and 36 positive samples (clinically confirmed SFTS patients); among the positive samples, 14 were clinically diagnosed as mild SFTS and 22 were clinically diagnosed as severe SFTS.
[0080] (1) Real-time fluorescence quantitative PCR detection method (RT-PCR method) for SFTSV infection
[0081] Total RNA was extracted from the purified platelets using an RNA extraction kit, and the total RNA was reverse transcribed using a reverse transcription kit to obtain cDNA, which was amplified using a qPCR premix in a real-time fluorescence quantitative PCR instrument, wherein IFITM3 was the target gene for amplification, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was the internal reference gene for amplification, IFITM3 referred to the sequence of human IFITM3 (human-IFITM3), the primers of the target gene were H-IFITM3-F and H-IFITM3-R, the primers of the internal reference gene were GAPDH-F and GAPDH-R, and the sequences of the two pairs of primers were shown in the following table; the amplification program for reverse transcribing total RNA into cDNA: 95°C pre-denaturation for 30s; 95°C denaturation for 30s, 60°C annealing for 30s, and so on for 40 cycles; specific melting curve analysis of the amplified product: 95°C, 15s; 65°C-95°C, each increase of 0.3°C for 1min, until 95°C; and finally 95°C, 15min. In the melting curve, the final reaction at 95°C for 15 minutes is to verify the specificity of the primers. Due to repeated comparisons in the preliminary experiments, it was found that increasing the final reaction time at 95°C for 15 minutes is conducive to further verifying the usability of the primers, especially after increasing the reaction time at 95°C for 15 minutes, primer pairing with non-specific amplification can be excluded.
[0082] The expression change of the target gene IFITM3 relative to the internal reference gene GAPDH was calculated by relative quantitative method (ΔΔCT method). The scatter plot of the RT-PCR amplification results is shown in Figure 4 As shown, the calculation results of the relative quantitative method are displayed on the vertical axis in logarithmic form.
[0083] Table 1: Primer sequence list
[0084]
[0085] IFITM3 can be used as a marker for SFTSV infection and can be used to distinguish and detect SFTSV infection using a real-time fluorescence quantitative amplification method. The test results of 44 random clinical samples using the real-time fluorescence quantitative amplification method of the present invention were compared with the positive and negative coincidence rate and the total coincidence rate of the third-party reagent (DAAN GENE's severe febrile thrombocytopenia syndrome virus nucleic acid detection kit (qRT-PCR probe method), the target gene is the highly conserved region of SFTSV) detected by the third-party reagent (regarding the public description of the target gene in the third-party reagent, technicians in this field generally default to the structural gene S gene); the specific relative quantitative values are as follows Figure 4 As shown, it can be seen that after logarithmic calculation, the relative quantitative results of the target gene IFITM3 expression of negative samples are located around 0, and the relative quantitative results of the target gene IFITM3 expression of positive samples are concentrated between 1-3, which is much higher than that of negative samples. That is, the corresponding relative quantitative results after classification of negative samples and positive samples are reflected in two obvious clusters, and the difference in the expression of the target gene IFITM3 under two different conditions (negative samples and positive samples) is significant (****p<0.0001).
[0086] The present invention provides a real-time fluorescence quantitative PCR detection kit for SFTSV infection, wherein the marker IFITM3 is used as the amplification target gene, the primers of the marker IFITM3 are H-IFITM3-F and H-IFITM3-R, and the corresponding nucleotide sequences are shown in SEQ ID NO:1 and SEQ ID NO:2 in the sequence table; GAPDH is used as the amplification internal reference gene, the primers of GAPDH are GAPDH-F and GAPDH-R, and the corresponding nucleotide sequences are shown in SEQ ID NO:3 and SEQ ID NO:4 in the sequence table. The real-time fluorescence quantitative PCR detection kit is based on two pairs of primers to jointly perform real-time fluorescence quantitative PCR amplification, the amplification procedure is as described above, and the logarithm of the relative quantitative value is calculated based on the amplification result of IFITM3 to GAPDH; according to the logarithm of the relative quantitative value of the amplification result, the threshold is set to 1, when the logarithm is greater than 1, it is determined that the test result is positive, when the logarithm is between -0.5 and 0.5, it is determined that the test result is negative, when the logarithm is greater than 0.5 and less than 1, re-testing can be performed or re-testing can be performed with a third-party reagent. The present invention uses human IFITM3 as the target gene of the real-time fluorescence quantitative amplification method, which can effectively overcome the dependence of traditional viral nucleic acid detection reagents on the stability of the known target gene sequence of the virus strain, can detect all SFTSV virus types, and qualitatively distinguish samples under two different conditions. However, the relative quantitative values of the RT-PCR test results cannot accurately quantitatively distinguish patients with different progressions (mild and severe).
[0087] (2) Flow cytometric detection of SFTSV infection
[0088] Although Western blot experiments can prove that the expression of IFITM3 is significantly different in different disease processes of patients diagnosed with SFTS, it is limited by the unfavorable conditions such as low sensitivity, complex operation, long time, strong equipment dependence and high sample processing requirements of Western blot, and is not suitable for the development of semi-quantitative detection of different processes of SFTSV infection. Based on the verification that the above-mentioned flow cytometry can be used for IFITM3 upregulation, the present invention further optimizes the flow cytometry detection method by introducing viral NP protein, and establishes a flow cytometry detection method for distinguishing disease processes. The detection objects are the 44 samples (8 negative samples, 14 positive samples of SFTS mild disease, 22 positive samples of SFTS severe disease, and the subjects from which the 22 positive samples of SFTS severe disease came, 4 subjects had clinical treatment outcomes of death), and the specific operations are as follows:
[0089] 1) Take out 100 μL / well of the separated single cell suspension (purified platelets) and place it in a 96-well plate;
[0090] 2) Add 200 μL / well flow cytometry permeabilization buffer to resuspend evenly, incubate at room temperature in the dark for 30 minutes, centrifuge at medium to low speed, and discard the supernatant;
[0091] 3) Add 200 μL / well 1× flow cytometry permeabilization buffer and centrifuge at room temperature at medium to low speed, and discard the supernatant;
[0092] 4) Add 1× flow cytometry permeabilization buffer to adjust the volume to 100 μL / well and resuspend;
[0093] 5) IFITM3 monoclonal antibody and SFTSVNP polyclonal antibody were added at a ratio of 1:2000, incubated at room temperature in the dark for 30 minutes, centrifuged at medium to low speed, and discarded the supernatant;
[0094] 6) Add 1× flow cytometry permeabilization buffer again to adjust the volume to 100 μL / well and resuspend;
[0095] 7) Add two different labeled goat anti-mouse secondary antibodies and goat anti-rabbit secondary antibodies corresponding to the primary antibody at a dilution of 1:2000, incubate at room temperature in the dark for 15 minutes, centrifuge at medium to low speed, and discard the supernatant;
[0096] 8) After adding 100 μL PIPES buffer to resuspend the cells, the samples were loaded onto a flow cytometer for detection and analysis, with the horizontal axis representing FITC-IFITM3 and the vertical axis representing APC-SFTSVNP;
[0097] Different from the above-mentioned flow cytometry experiment verifying that the candidate marker IFITM3 expression has a significant correlation, in the flow cytometry detection method for distinguishing the disease process of the present invention, the primary antibody used for incubation is a mixed incubation of IFITM3 monoclonal antibody and SFTSVNP polyclonal antibody, and the secondary antibody is a goat anti-mouse secondary antibody and a goat anti-rabbit secondary antibody corresponding to the primary antibody and labeled with two different markers, wherein the goat anti-rabbit secondary antibody is specifically Alexa 647-labeled goat anti-rabbit IgG H&L, configured for detection in the APC channel in fluorescence detection; goat anti-mouse secondary antibody is specifically Alexa 488-labeled goat anti-mouse IgG H&L was used for fluorescence detection in the FITC channel; 44 clinical samples were tested by flow cytometry, and the test results of negative samples from 8 healthy donors are as follows Figure 5 As shown, the percentages of IFITM3 and SFTSVNP expression were all negative. The test results of positive samples from 14 patients diagnosed with mild SFTS were as follows Figure 6 As shown, the positive sample test results from 22 SFTS patients with severe disease are as follows Figure 7 As shown, compared with the clinical diagnosis results, the negative and positive coincidence rates of the flow cytometry test results were both 100%. Specifically, the test results for distinguishing mild SFTS from severe SFTS in positive samples were slightly different: the coincidence rate for distinguishing mild SFTS was 12÷14=85.71%, and the coincidence rate for distinguishing severe SFTS was 19÷22=86.36%, and the negative coincidence rate = specificity = 100%. Among them, the coincidence rate for distinguishing severe SFTS in 4 cases with clinical death was 100%. The specific results are shown in Table 2 below.
[0098] Table 2 Comparison of flow cytometry results and clinical diagnosis results
[0099]
[0100] The detection data of negative samples detected by flow cytometry were used as negative control values, and flow cytometry was performed on positive samples from 36 confirmed SFTS patients. The detection data of positive samples detected by flow cytometry were further compared and analyzed with the negative control values, focusing on verifying the flow cytometry data of the 36 positive samples. First, the values of the percentage of expression of IFITM3 and SFTSVNP in the flow cytometry results were compared separately. The positive samples (including two types of positive samples from mild SFTS and severe SFTS) were greater than the negative samples and were considered to be IFITM3% positive + SFTSV NP% positive, that is, the percentage of IFITM3 expression and the percentage of SFTSVNP expression in the positive samples detected by flow cytometry were double positive. Secondly, the percentage values of IFITM3 and SFTSVNP expression were added and recorded as M, where the sum corresponding to the negative samples was recorded as M1, and the sum corresponding to the positive samples was recorded as M2. The M value was taken logarithmically and plotted as shown in the figure Figure 8 As shown in A, it can be seen that: comparing the values of M2 of the two types of positive samples of SFTS mild and SFTS severe, not only is there a significant difference between SFTS mild and SFTS severe (*p<0.05), but also SFTS severe is much higher than SFTS mild, that is, M2 (severe) > M2 (mild). Third, the average value of the summed value M2 of the positive samples of SFTS mild is 0.12±0.08%, and the average value of the summed value M2 of the positive samples of SFTS severe is 4.49%±0.74%. Fourth, based on the survival status of SFTSV-infected patients with clinical backgrounds provided by the hospital, the sum of the double positive values (M2) of IFITM3% and NP% detected by flow cytometry of positive samples collected within one week of admission was further verified. The survival rate of the subjects corresponding to M2 lower than 0.20% was 100%, and the M2 of the 22 positive samples of severe SFTS was generally higher than 0.20%. Among the corresponding subjects, 4 cases had clinical treatment outcomes of death, and the survival rate of the corresponding 22 subjects was 81.82% (18 / 22), which was basically equivalent to the survival rate results of severe SFTS in the epidemiological survey. Therefore, 0.20% can be used as a benchmark value to distinguish between mild SFTS and severe SFTS for further analysis and verification. Fourth, based on the flow cytometric test results of positive samples, a graph was drawn with IFITM3% as the horizontal axis and SFTSVNP% as the vertical axis, as shown below. Figure 8 As shown in B, it can be seen that: the higher the IFITM3% (equivalent to the higher IFITM3 expression level), the higher the corresponding NP% (equivalent to the higher expression of SFTSVNP protein in SFTS-confirmed patients), the more severe the condition of the corresponding SFTS-confirmed subjects, that is, the IFITM3 expression level detected by flow cytometry in the platelets of SFTS-confirmed patients showed a significant positive correlation with the SFTSVNP protein expression level (p=0.0293); Fifth, the average value of the corresponding summed value M1 of negative samples was 0.02±0.01%.
[0101] The present invention provides a flow cytometry detection method for SFTSV infection. The detection sample is a single-cell suspension (purified platelets), with IFITM3 as the detection marker and SFTSVNP as the reference marker. The core steps of the detection method include: adding the primary antibodies (IFITM3 monoclonal antibody and SFTSVNP polyclonal antibody) at a ratio of 1:2000, incubating in the dark at room temperature for 30 minutes, then centrifuging and discarding the supernatant; adding the corresponding secondary antibodies (two different labeled goat anti-mouse secondary antibodies and goat anti-rabbit secondary antibodies) at a ratio of 1:2000, incubating in the dark at room temperature for 15 minutes, then centrifuging and discarding the supernatant; after resuspension, performing flow cytometry detection and analysis, with the abscissa being the labeled IFITM3 and the ordinate being the labeled SFTSVNP protein; using the double positivity of IFITM3 and SFTSV NP as an indicator for predicting the disease progression of SFTS patients. The detection process uses purified platelets from negative samples as negative reference products, and the test samples are also required to be single-cell suspensions (purified platelets) after pretreatment. The sum of the percentages of IFITM3 and SFTSVNP expressions obtained from the flow cytometry negative control and the test sample are denoted as M1 and M2 respectively; using M2 > M1 ± SD as the determination criterion for distinguishing positive results (SFTSV infection), where the value of M1 ± SD is 0.02 ± 0.01%; in the positive results, if M1 ± SD < M2 ≤ 0.12 ± 0.08%, the disease course of the subject from whom the test sample is derived can be further classified as mild SFTS, and if M2 > 0.12 ± 0.08%, the disease course of the subject from whom the test sample is derived can be further classified as severe SFTS; through the digital determination criterion, it is beneficial to improve the screening efficiency for in vitro detection and distinguishing whether the subject from whom the test sample is derived is a severe SFTS patient.
[0102] The present invention provides a flow cytometry detection kit for distinguishing SFTSV infection. The detection sample is a single-cell suspension or purified platelets obtained from a blood sample of a subject after platelet separation pretreatment; the flow cytometry detection kit includes a flow cytometry fixation and permeabilization solution, a flow cytometry permeabilization buffer, an IFITM3 monoclonal antibody, an SFTSVNP polyclonal antibody, and two different labeled goat anti-mouse secondary antibodies and goat anti-rabbit secondary antibodies corresponding to the IFITM3 monoclonal antibody and the SFTSVNP polyclonal antibody. By detecting the double positive rate of the IFITM3 protein and the SFTSVNP protein through a flow cytometer, the screening efficiency for in vitro detecting whether the subject from whom the test sample is derived is positive for SFTSV infection and whether it is likely to progress to severe SFTS is improved.
[0103] The present invention provides a detection application based on the SFTSV infection marker IFITM3 and using it to distinguish SFTSV infection. Based on the SFTSV infection marker IFITM3, the present invention provides a real-time fluorescence quantitative PCR detection method for distinguishing SFTSV infection and a real-time fluorescence quantitative PCR detection kit for distinguishing SFTSV infection by introducing the internal reference gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase); by jointly detecting the SFTSV NP protein and the marker IFITM3, a flow cytometric detection method for distinguishing SFTSV infection and a flow cytometric detection kit for distinguishing SFTSV infection are provided, and the baseline level of the double positive rate determination of IFITM3 and SFTSV NP is clarified for the flow cytometric detection results, which can be used to distinguish SFTSV infection and further distinguish whether the subject from which the detection sample is derived is likely to progress to severe SFTS. Therefore, the present invention is based on the application of the SFTSV infection marker IFITM3, which overcomes the strict requirements of traditional SFTSV nucleic acid detection on sample timeliness and the limitations of unknown strain sequence coverage. It can not only be used to distinguish SFTSV infection, but also can be used to further distinguish between mild SFTS and severe SFTS, especially for the early differentiation and identification of those who may progress to severe SFTS, and will have good clinical application value.
[0104] The specific embodiments of the present invention have been described in detail so that those skilled in the art will be easily understood. However, based on the teachings of the present invention that have been disclosed in all descriptions, those skilled in the art will understand that various modifications, changes and substitutions can be made to the details, and these changes are within the scope of protection of the present invention. The full scope of the present invention is given by the attached claims and any equivalents thereof.
Claims
1. A marker IFITM3 for SFTSV infection detection, characterized in that: The marker IFITM3 is used in the detection to distinguish whether it is SFTSV infection. The detection is implemented in a pretreated blood sample. The pretreatment is to separate platelets from the blood sample to obtain a purified platelet stock solution. The purity of the platelets in the stock solution is greater than 90%.
2. The marker IFITM3 for SFTSV infection detection according to claim 1, characterized in that: The platelet separation adopts immunomagnetic bead sorting technology, and the steps are as follows: 1) Add platelet activation inhibitor, mix well, and centrifuge at low speed to obtain platelet-rich plasma PRP; 2) 75% platelet-rich plasma PRP was pipetted and centrifuged at medium to low speed, and the plasma supernatant was discarded to obtain platelet precipitate; 3) Prepare the sorting buffer solution; 4) taking a small amount of the sorting buffer working solution to resuspend the platelet precipitate, adding the beads in a ratio of sorting buffer working solution: beads = 9:1, mixing, and incubating at room temperature; the volume of the incubation solution is counted as a single volume; 5) Add 10 times the volume of sorting buffer working solution, mix again, centrifuge at medium to low speed, discard the supernatant, and obtain the microbead-labeled platelet precipitate; 6) Resuspend the platelet precipitate with 2-3 times the volume of the sorting buffer working solution to obtain a platelet suspension; 7) Place the microcolumn on the magnetic separator, add 2-3 times the volume of the separation buffer solution to rinse the microcolumn once, and discard the waste solution; 8) adding the platelet suspension to the microcolumn for magnetic adsorption, repeating the magnetic adsorption operation twice, and discarding the platelet suspension flowing out of the microcolumn after the second magnetic adsorption; 9) Take 2-3 times the volume of sorting buffer working solution to rinse the microcolumn, and repeat the rinsing operation 3 times; 10) Remove the microcolumn from the magnetic separator, place it in a new centrifuge tube, add 5 times the volume of sorting buffer working solution to make the platelets adsorbed in the microcolumn flow out to the centrifuge tube below along with the sorting buffer working solution, and obtain a single cell suspension, which is the purified platelet; 11) Using flow cytometry to detect the purity of platelets in the single cell suspension.
3. A real-time fluorescence quantitative PCR detection method for distinguishing SFTSV infection, characterized in that: The marker IFITM3 described in claim 1 is used as the amplification target gene, and glyceraldehyde-3-phosphate dehydrogenase GAPDH is used as the amplification internal reference gene. The relative quantitative value is calculated by the amplification result of IFITM3 relative to glyceraldehyde-3-phosphate dehydrogenase GAPDH to distinguish whether it is SFTSV infection.
4. A real-time fluorescence quantitative PCR detection kit for distinguishing SFTSV infection, characterized in that: The marker IFITM3 for detecting SFTSV infection according to claim 1 is used as the amplification target gene, wherein the primers of the marker IFITM3 are H-IFITM3-F and H-IFITM3-R, and the corresponding nucleotide sequences are shown in SEQ ID NO: 1 and SEQ ID NO: 2 in the sequence table; glyceraldehyde-3-phosphate dehydrogenase GAPDH is used as the amplification internal reference gene, and the primers of glyceraldehyde-3-phosphate dehydrogenase GAPDH are GAPDH-F and GAPDH-R, and the corresponding nucleotide sequences are shown in SEQ ID NO: 3 and SEQ ID NO: 4 in the sequence table.
5. A flow cytometric detection method for distinguishing SFTSV infection, characterized in that: Using the SFTSV NP protein and the marker IFITM3 described in claim 1 as the target proteins for detection, and using the quantitative values of SFTSV NP and the marker IFITM3 as the discrimination criteria for SFTSV infection.
6. The flow cytometry detection method according to claim 5, characterized in that: The quantitative value is the sum of the positive percentages of IFITM3 and SFTSV NP expression obtained by flow cytometry, denoted as M; the sum value corresponding to the negative detection sample is M1, and the sum value corresponding to the positive detection sample is M2.
7. The flow cytometry detection method according to claim 6, characterized in that: The discrimination criteria include: If the quantitative value M2 > M1 ± SD, the test result is determined to be positive; and among the positive results, If M1 ± SD < M2 ≤ 0.12 ± 0.08%, the test result is determined to be mild SFTS; If the quantitative value M2 > 0.12 + 0.08%, the test result is determined to be severe SFTS.
8. A flow cytometric detection kit for distinguishing SFTSV infection, characterized in that: The test sample is purified platelets; using the SFTSV NP protein and the marker IFITM3 described in claim 1 as the target proteins for detection; the flow cytometry detection kit includes an anti-IFITM3 monoclonal antibody, an anti-SFTSV NP polyclonal antibody, two different labeled secondary antibodies corresponding to the anti-IFITM3 monoclonal antibody and the anti-SFTSV NP polyclonal antibody, and reagents for flow cytometry detection.
9. The flow cytometry detection kit according to claim 8, characterized in that: The secondary antibodies are a goat anti-mouse secondary antibody corresponding to the anti-IFITM3 monoclonal antibody and a goat anti-rabbit secondary antibody corresponding to the anti-SFTSV NP polyclonal antibody; the two different labels are either FITC label and APC label, or Alexa Fluor 488 label and Alexa Fluor 647 label; the reagents for flow cytometry detection include a flow cytometry fixation and permeabilization solution and a flow cytometry permeabilization buffer.
10. Use of the marker IFITM3 in preparing a kit for detecting SFTSV infection, characterized in that: The kit uses either the RT-PCR method or the immunological method.
Citation Information
Cited By
Application of flow type detection reagent in bleeding risk grade classification product of tumor diseases
CN120778688A
